دورية أكاديمية
أعرض في EDS

Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.

التفاصيل البيبلوغرافية
العنوان: Borderline atypical ductal hyperplasia/low-grade ductal carcinoma in situ on breast needle core biopsy should be managed conservatively.
المؤلفون: Vandenbussche CJ; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231-2410, USA., Khouri N, Sbaity E, Tsangaris TN, Vang R, Tatsas A, Cimino-Mathews A, Argani P
المصدر: The American journal of surgical pathology [Am J Surg Pathol] 2013 Jun; Vol. 37 (6), pp. 913-23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 7707904 Publication Model: Print Cited Medium: Internet ISSN: 1532-0979 (Electronic) Linking ISSN: 01475185 NLM ISO Abbreviation: Am J Surg Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2015- > : Philadelphia, PA : Wolters Kluwer Health, Inc.
Original Publication: New York, Masson.
مواضيع طبية MeSH: Breast Neoplasms/*pathology , Breast Neoplasms/*surgery , Carcinoma, Intraductal, Noninfiltrating/*pathology , Carcinoma, Intraductal, Noninfiltrating/*surgery, Biopsy, Large-Core Needle ; Female ; Humans ; Hyperplasia/pathology ; Hyperplasia/surgery
مستخلص: The differential diagnosis of low-nuclear grade intraductal epithelial proliferations of the breast includes atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). This distinction can be difficult on core needle biopsy (CNB) but can have significant clinical ramifications. We examined the clinical course of patients diagnosed on CNB with borderline ADH/DCIS lesions [marked ADH (MADH)] at our institution. A total of 74 patients were diagnosed with MADH on CNB and underwent an excisional biopsy (EB). The majority of these CNBs reviewed at outside hospitals had been classified as DCIS. Twenty patients (27%) had benign findings or lobular neoplasia in their EB, 18 (24%) had ADH, 33 (45%) had DCIS, and 3 (4%) had DCIS and invasive ductal carcinoma (IDC). Among the 38 patients who were not diagnosed with DCIS or IDC on EB, no patient underwent further surgery or radiation postoperatively. Thirty-seven of these 38 patients had no recurrences, whereas 1 patient developed a "recurrence" that on our review was likely residual localized MADH. The mean follow-up for these patients was 54 months. Of the 36 patients diagnosed with DCIS or IDC on EB, <20% required mastectomy. On review, MADH involving an intermediate-sized duct on CNB and the amount of residual lesion on imaging was significantly associated with DCIS or IDC on EB. Conversely, MADH involving columnar cell lesions and the presence of calcification on CNB were significantly associated with benign pathology on EB. In conclusion, our study provides preliminary data that justify a conservative approach to borderline ADH/DCIS lesions on CNB: that is, diagnose as MADH and treat by conservative excision.
References: Cancer. 1985 Jun 1;55(11):2698-708. (PMID: 2986821)
Cancer. 1999 Aug 1;86(3):429-38. (PMID: 10430251)
J Surg Oncol. 2007 Jun 15;95(8):610-3. (PMID: 17221862)
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9. (PMID: 12714683)
Oncology (Williston Park). 2011 Aug;25(9):852-6. (PMID: 21936451)
Cancer. 2005 Jun 15;103(12):2481-4. (PMID: 15884091)
J Clin Oncol. 2006 Mar 1;24(7):1031-6. (PMID: 16461781)
Ann Surg Oncol. 2009 Oct;16(10):2682-90. (PMID: 19653046)
J Clin Pathol. 2004 Sep;57(9):897-902. (PMID: 15333647)
Am J Surg Pathol. 2002 Sep;26(9):1095-110. (PMID: 12218567)
Adv Anat Pathol. 2009 Jul;16(4):183-95. (PMID: 19546607)
J Clin Oncol. 2009 Nov 10;27(32):5319-24. (PMID: 19826126)
Mod Pathol. 2010 May;23 Suppl 2:S36-45. (PMID: 20436501)
Ann Surg Oncol. 2012 Apr;19(4):1129-36. (PMID: 21975859)
Histopathology. 2003 Apr;42(4):331-6. (PMID: 12653944)
Am J Surg Pathol. 2001 Aug;25(8):1017-21. (PMID: 11474285)
N Engl J Med. 1985 Jan 17;312(3):146-51. (PMID: 3965932)
J Surg Oncol. 2007 Jun 15;95(8):605-9. (PMID: 17192948)
Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301. (PMID: 9149887)
Adv Anat Pathol. 2003 May;10(3):113-24. (PMID: 12717115)
Breast J. 2010 Sep-Oct;16 Suppl 1:S5-9. (PMID: 21050312)
Am J Surg Pathol. 2005 Dec;29(12):1625-32. (PMID: 16327435)
N Engl J Med. 1999 May 13;340(19):1455-61. (PMID: 10320383)
Breast Cancer Res Treat. 2008 Jun;109(3):405-16. (PMID: 17687650)
معلومات مُعتمدة: P30 CA006973 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20130420 Date Completed: 20130718 Latest Revision: 20211021
رمز التحديث: 20240513
مُعرف محوري في PubMed: PMC3991135
DOI: 10.1097/PAS.0b013e31828ba25c
PMID: 23598968
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-0979
DOI:10.1097/PAS.0b013e31828ba25c